$EHC
Encompass Health Corp

2014 Q4 Form 10-Q Financial Statement

#000078516114000067 Filed on October 28, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2014 Q2
Revenue $613.4M $596.9M $604.4M
YoY Change 7.22% 5.83% 7.07%
Cost Of Revenue $29.90M $26.60M $27.80M
YoY Change 10.33% 4.31% 4.51%
Gross Profit $576.9M $562.1M $567.3M
YoY Change 6.56% 5.96% 6.86%
Gross Profit Margin 94.05% 94.17% 93.86%
Selling, General & Admin $348.9M $331.8M $327.8M
YoY Change 10.59% 5.6% 3.34%
% of Gross Profit 60.48% 59.03% 57.78%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $27.50M $27.40M $26.40M
YoY Change 9.13% 12.76% 14.29%
% of Gross Profit 4.77% 4.87% 4.65%
Operating Expenses $467.8M $448.6M $439.7M
YoY Change 10.75% 6.63% 4.87%
Operating Profit $109.1M $113.5M $127.6M
YoY Change -8.32% 3.37% 14.34%
Interest Expense -$23.80M -$25.90M -$25.20M
YoY Change 1.28% 11.16% 19.43%
% of Operating Profit -21.81% -22.82% -19.75%
Other Income/Expense, Net $1.100M $200.0K $28.20M
YoY Change -15.38% -66.67% 1384.21%
Pretax Income $74.10M $87.80M $130.6M
YoY Change -21.67% -19.0% 41.34%
Income Tax $19.30M $22.10M $36.50M
% Of Pretax Income 26.05% 25.17% 27.95%
Net Earnings $42.10M $50.10M $83.10M
YoY Change -13.91% -13.92% -49.7%
Net Earnings / Revenue 6.86% 8.39% 13.75%
Basic Earnings Per Share $0.46 $0.55 $0.93
Diluted Earnings Per Share $0.44 $0.52 $0.85
COMMON SHARES
Basic Shares Outstanding 87.75M shares 86.50M shares 86.70M shares
Diluted Shares Outstanding 100.5M shares 100.6M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $66.70M $272.3M $65.80M
YoY Change 3.41% 318.92% -4.22%
Cash & Equivalents $66.70M $272.3M $65.80M
Short-Term Investments
Other Short-Term Assets $108.3M $110.2M $103.9M
YoY Change -5.91% -7.55% -6.9%
Inventory
Prepaid Expenses
Receivables $323.2M $261.6M $272.3M
Other Receivables $13.90M $0.00 $0.00
Total Short-Term Assets $686.6M $783.0M $580.9M
YoY Change 18.3% 36.15% -1.79%
LONG-TERM ASSETS
Property, Plant & Equipment $1.020B $994.6M $976.5M
YoY Change 11.99% 11.32% 23.09%
Goodwill $1.084B $491.7M $34.80M
YoY Change 137.25% 7.55% 154.01%
Intangibles $306.1M $99.90M $103.3M
YoY Change 247.05% 14.43% 19.01%
Long-Term Investments $8.200M
YoY Change -56.61%
Other Assets $162.5M $169.5M $148.0M
YoY Change 12.77% 29.59% 7.17%
Total Long-Term Assets $2.702B $2.011B $1.996B
YoY Change 38.27% 1.49% 3.93%
TOTAL ASSETS
Total Short-Term Assets $686.6M $783.0M $580.9M
Total Long-Term Assets $2.702B $2.011B $1.996B
Total Assets $3.388B $2.794B $2.577B
YoY Change 33.69% 9.29% 2.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $53.40M $54.80M $55.70M
YoY Change -13.73% 1.11% -2.79%
Accrued Expenses $144.5M $251.4M $243.6M
YoY Change 26.09% -2.41% -4.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $20.80M $208.5M
YoY Change 69.11%
Total Short-Term Liabilities $364.3M $514.7M $299.3M
YoY Change 16.91% 65.07% -3.95%
LONG-TERM LIABILITIES
Long-Term Debt $2.090B $1.441B $1.475B
YoY Change 38.88% 10.35% 11.78%
Other Long-Term Liabilities $37.50M $139.7M $141.1M
YoY Change -14.77% -0.5% 7.38%
Total Long-Term Liabilities $37.50M $139.7M $141.1M
YoY Change -14.77% -0.5% 7.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $364.3M $514.7M $299.3M
Total Long-Term Liabilities $37.50M $139.7M $141.1M
Total Liabilities $2.591B $2.096B $1.916B
YoY Change 32.26% 19.19% 8.67%
SHAREHOLDERS EQUITY
Retained Earnings -$1.879B -$1.921B -$1.971B
YoY Change -10.57% -10.64% -10.73%
Common Stock $1.000M $1.000M $1.000M
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $458.7M $458.1M $457.6M
YoY Change 13.37% 13.33% 13.27%
Treasury Stock Shares 16.27M shares 16.26M shares 16.24M shares
Shareholders Equity $473.2M $449.6M $413.7M
YoY Change
Total Liabilities & Shareholders Equity $3.388B $2.794B $2.577B
YoY Change 33.69% 9.29% 2.58%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2014 Q2
OPERATING ACTIVITIES
Net Income $42.10M $50.10M $83.10M
YoY Change -13.91% -13.92% -49.7%
Depreciation, Depletion And Amortization $27.50M $27.40M $26.40M
YoY Change 9.13% 12.76% 14.29%
Cash From Operating Activities $70.20M $139.6M $128.0M
YoY Change -30.43% -2.1% 21.44%
INVESTING ACTIVITIES
Capital Expenditures -$41.40M -$46.00M -$36.90M
YoY Change 21.41% -54.68% -13.58%
Acquisitions $0.00 $15.90M
YoY Change -44.98%
Other Investing Activities -$673.2M -$9.300M -$2.300M
YoY Change -13300.0% -263.16% -78.7%
Cash From Investing Activities -$714.6M -$55.30M -$39.20M
YoY Change 2364.14% -42.28% -26.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 438.8M 122.2M -76.10M
YoY Change -706.08% -341.98% 20.22%
NET CHANGE
Cash From Operating Activities 70.20M 139.6M 128.0M
Cash From Investing Activities -714.6M -55.30M -39.20M
Cash From Financing Activities 438.8M 122.2M -76.10M
Net Change In Cash -205.6M 206.5M 12.70M
YoY Change 41020.0% -5681.08% -211.4%
FREE CASH FLOW
Cash From Operating Activities $70.20M $139.6M $128.0M
Capital Expenditures -$41.40M -$46.00M -$36.90M
Free Cash Flow $111.6M $185.6M $164.9M
YoY Change -17.33% -23.97% 11.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
23100000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
153300000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
51000000 USD
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
54800000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
61900000 USD
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
261600000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
261800000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-100000 USD
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-100000 USD
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2828000000 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2849400000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19300000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19000000 USD
CY2014Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
24200000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares
CY2013Q4 us-gaap Assets
Assets
2534400000 USD
CY2014Q3 us-gaap Assets
Assets
2794000000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
580400000 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
783000000 USD
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
181600000 USD
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
278000000 USD
CY2013Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
59300000 USD
CY2014Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
50100000 USD
CY2013Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
574800000 USD
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
1811300000 USD
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
1734400000 USD
CY2014Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
596900000 USD
us-gaap Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual
BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
2600000 USD
us-gaap Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual
BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
15400000 USD
CY2014Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
91900000 USD
CY2014Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
12100000 USD
CY2014Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
7800000 USD
CY2014Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
70000000 USD
CY2014Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities
14100000 USD
CY2014Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
30400000 USD
us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Fair Value1
BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
0 USD
CY2013Q3 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Fair Value1
BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
0 USD
CY2014Q3 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Fair Value1
BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
0 USD
us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Fair Value1
BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
-35000000 USD
us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
27200000 USD
us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
0 USD
CY2013Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
88900000 USD
CY2014Q3 us-gaap Capital Lease Obligations
CapitalLeaseObligations
84300000 USD
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
5100000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64500000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
272300000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
132800000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65000000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-67800000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
207800000 USD
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-1000000 USD
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-1400000 USD
CY2014Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2900000 shares
CY2004Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10000000 shares
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.18
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.57
CY2013Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.18
CY2014Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.21
CY2014Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.21
CY2014Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.18
CY2014Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.18
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
104011178 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
102648302 shares
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
1000000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1000000 USD
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
50000000 USD
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.68
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3700000 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
58300000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
179900000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
273100000 USD
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
300000 USD
CY2014Q3 us-gaap Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
5100000 USD
us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
5100000 USD
CY2013Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
139000000 USD
CY2013Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
354300000 USD
CY2014Q3 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
255300000 USD
CY2014Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30300000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
69500000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
80200000 USD
CY2014Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27400000 USD
CY2013Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24300000 USD
CY2014Q3 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
1600000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
44300000 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
14100000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
42500000 USD
CY2014Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
14700000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
224200000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
315600000 USD
CY2014Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
64700000 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
72400000 USD
CY2014Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
32.7869 shares
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
475200000 USD
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
424900000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1315600000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1410100000 USD
CY2014Q3 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
1649900000 USD
CY2013Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
1517500000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-20800000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
81600000 USD
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
139000000 USD
CY2014Q3 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
138900000 USD
CY2014Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
394200000 USD
CY2014Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
138900000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6300000 USD
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.86
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.85
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.58
CY2014Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
11300000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
9400000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
9600000 USD
CY2013Q3 us-gaap Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items
EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
4400000 USD
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
50600000 USD
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
15900000 USD
CY2014Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
1600000 USD
CY2013Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
5700000 USD
us-gaap Dividends Preferred Stock
DividendsPreferredStock
17200000 USD
us-gaap Dividends Preferred Stock
DividendsPreferredStock
4700000 USD
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
4700000 USD
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
17200000 USD
CY2013Q4 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
0 USD
CY2014Q3 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
0 USD
CY2013Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0 USD
CY2014Q3 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0 USD
CY2014Q3 us-gaap Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items
EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
4200000 USD
us-gaap Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items
EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
28200000 USD
us-gaap Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items
EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
18400000 USD
CY2013Q3 us-gaap Equity Method Investment Summarized Financial Information Net Income Loss
EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
4400000 USD
CY2014Q3 us-gaap Equity Method Investment Summarized Financial Information Net Income Loss
EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
4200000 USD
us-gaap Equity Method Investment Summarized Financial Information Net Income Loss
EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
28200000 USD
us-gaap Equity Method Investment Summarized Financial Information Net Income Loss
EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
18400000 USD
CY2014Q3 us-gaap Equity Method Investment Summarized Financial Information Revenue
EquityMethodInvestmentSummarizedFinancialInformationRevenue
7800000 USD
us-gaap Equity Method Investment Summarized Financial Information Revenue
EquityMethodInvestmentSummarizedFinancialInformationRevenue
44100000 USD
CY2013Q3 us-gaap Equity Method Investment Summarized Financial Information Revenue
EquityMethodInvestmentSummarizedFinancialInformationRevenue
16200000 USD
us-gaap Equity Method Investment Summarized Financial Information Revenue
EquityMethodInvestmentSummarizedFinancialInformationRevenue
55400000 USD
CY2013Q3 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
52000000 USD
CY2014Q3 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
15600000 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27500000 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28800000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
88500000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
88400000 USD
CY2014Q3 us-gaap Goodwill
Goodwill
491700000 USD
CY2013Q4 us-gaap Goodwill
Goodwill
456900000 USD
CY2014Q2 us-gaap Goodwill
Goodwill
34800000 USD
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
13700000 USD
CY2013Q3 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0 USD
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
34800000 USD
CY2014Q3 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0 USD
CY2014Q3 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
596900000 USD
us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
1701100000 USD
us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
1792500000 USD
CY2013Q3 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
564000000 USD
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1100000 USD
CY2013Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1100000 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
51000000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
275900000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
177100000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
59100000 USD
us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
42500000 USD
us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
44300000 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
14700000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
14100000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
312800000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
300600000 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
87800000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
108400000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
318400000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
221400000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
73200000 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
65700000 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.56
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.87
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.96
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.61
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.53
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.59
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.82
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
8100000 shares
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9900000 USD
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
88200000 USD
CY2014Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
99900000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
73900000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
83500000 USD
CY2014Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
27800000 USD
CY2013Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
25300000 USD
CY2014Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
2300000 USD
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
6800000 USD
CY2013Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 USD
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 USD
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.69
CY2013Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-900000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-1200000 USD
CY2014Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-900000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
2800000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
2800000 USD
CY2014Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-900000 USD
CY2013Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-900000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-1200000 USD
CY2013Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.03
CY2014Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
CY2014Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
CY2013Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.03
CY2013Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2000000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
8200000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
8800000 USD
CY2014Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1900000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-17800000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
91400000 USD
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
22100000 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35200000 USD
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-4000000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
26500000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
48700000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-8900000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
4500000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-700000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-7600000 USD
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2013Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2014Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
8200000 shares
CY2014Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
3200000 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
11600000 shares
CY2013Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
11600000 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
3200000 shares
CY2014Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2600000 shares
CY2013Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2600000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2100000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2600000 shares
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
900000 USD
CY2014Q3 us-gaap Liabilities
Liabilities
2095800000 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2794000000 USD
CY2013Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
20300000 USD
CY2014Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
10800000 USD
us-gaap Labor And Related Expense
LaborAndRelatedExpense
817700000 USD
us-gaap Labor And Related Expense
LaborAndRelatedExpense
861400000 USD
CY2013Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
269500000 USD
CY2014Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
290000000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
1959000000 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2534400000 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-100000 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
514700000 USD
CY2014Q3 us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
12900000 USD
us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
38900000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
311600000 USD
CY2014Q3 us-gaap Line Of Credit
LineOfCredit
0 USD
CY2013Q4 us-gaap Line Of Credit
LineOfCredit
45000000 USD
CY2013Q4 us-gaap Loans Payable To Bank
LoansPayableToBank
0 USD
CY2014Q3 us-gaap Loans Payable To Bank
LoansPayableToBank
0 USD
CY2013Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
1505200000 USD
CY2014Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
1441400000 USD
CY2014Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
208500000 USD
CY2013Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
12300000 USD
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies and Other Commitments</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation By and Against Former Independent Auditor&#8212;</font></div><div style="line-height:120%;padding-bottom:13px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2003, claims on behalf of HealthSouth were brought against Ernst &amp; Young, LLP in a stockholder derivative lawsuit initially filed in the Circuit Court of Jefferson County, Alabama on August&#160;28, 2002 and captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker v. Scrushy</font><font style="font-family:inherit;font-size:10pt;">. The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> derivative litigation, including the claims against various other defendants and the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.9 billion</font><font style="font-family:inherit;font-size:10pt;"> judgment against Mr.&#160;Scrushy, our former chairman and chief executive officer, is more fully described in &#8220;Derivative Litigation&#8221; and &#8220;Litigation By and Against Former Independent Auditor&#8221; in Note 18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Other Commitments</font><font style="font-family:inherit;font-size:10pt;">, to the consolidated financial statements accompanying the 2013 Form 10-K. The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> complaint alleged that from 1996 through 2002, when Ernst &amp; Young served as our independent auditor, Ernst &amp; Young acted recklessly and with gross negligence in performing its duties, and specifically that Ernst &amp; Young failed to perform reviews and audits of our financial statements with due professional care as required by law and by its contractual agreements with us. The claims further alleged Ernst &amp; Young either knew of or, in the exercise of due care, should have discovered and investigated the fraudulent and improper accounting practices being directed by certain officers and employees, and should have reported them to our board of directors and the audit committee. The claims sought compensatory and punitive damages, disgorgement of fees received from us by Ernst &amp; Young, and attorneys&#8217; fees and costs. </font></div><div style="line-height:120%;padding-bottom:13px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March&#160;18, 2005, Ernst&#160;&amp; Young filed a lawsuit captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ernst&#160;&amp; Young LLP v. HealthSouth Corp.</font><font style="font-family:inherit;font-size:10pt;"> in the Circuit Court of Jefferson County, Alabama. The complaint alleged we provided Ernst&#160;&amp; Young with fraudulent management representation letters, financial statements, invoices, bank reconciliations, and journal entries in an effort to conceal accounting fraud. Ernst&#160;&amp; Young claimed that as a result of our actions, Ernst&#160;&amp; Young&#8217;s reputation had been injured and it incurred damages, expenses, and legal fees. On April&#160;1, 2005, we answered Ernst&#160;&amp; Young&#8217;s claims and asserted counterclaims related or identical to those asserted in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> action. Upon Ernst&#160;&amp; Young&#8217;s motion, the Alabama state court referred Ernst&#160;&amp; Young&#8217;s claims and our counterclaims to arbitration pursuant to a clause in the engagement agreements between HealthSouth and Ernst &amp; Young. In August 2006, we and the derivative plaintiffs agreed to jointly prosecute the claims against Ernst &amp; Young in arbitration.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trial phase of the arbitration process began on July 12, 2010 before a three-person arbitration panel selected under rules of the American Arbitration Association (the &#8220;AAA&#8221;). On December 18, 2012, the AAA panel granted Ernst &amp; Young&#8217;s motion to dismiss our claims on the grounds that HealthSouth was not permitted to pursue its claims since certain of its former officers and employees committed fraudulent acts. The panel also denied and dismissed Ernst&#160;&amp; Young&#8217;s claims against us. On December&#160;18, 2012, we, together with the stockholder derivative plaintiffs, filed a notice of appeal of the panel&#8217;s decision in the Circuit Court of Jefferson County, Alabama. On December 28, 2012, we filed a motion to vacate the decision. We asserted that the panel&#8217;s decision was contrary to the Federal Arbitration Act and the duties of a public accounting firm to its corporate clients, and that the arbitrators exceeded their authority by entering an award contrary to Alabama law. On April 25, 2013, the court denied our motion to vacate. On June 4, 2013, we filed a notice of appeal to the Supreme Court of Alabama seeking review of the circuit court's denial of our motion to vacate the arbitration panel's decision. On June 13, 2014, the Supreme Court of Alabama affirmed the decision by the circuit court. On June 27, 2014, we filed an application for rehearing with the Supreme Court of Alabama. On August 22, 2014, the Supreme Court of Alabama denied our application, and as a result, we consider this litigation matter concluded.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General Medicine Action&#8212;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August&#160;16, 2004, General Medicine, P.C. filed a lawsuit against us captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">General Medicine, P.C. v. HealthSouth Corp.</font><font style="font-family:inherit;font-size:10pt;"> seeking the recovery of allegedly fraudulent transfers involving assets of Horizon/CMS Healthcare Corporation, a former subsidiary of HealthSouth. The lawsuit is pending in the Circuit Court of Jefferson County, Alabama (the &#8220;Alabama Action&#8221;).</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General Medicine&#8217;s underlying claim against Horizon/CMS originates from a services contract entered into in 1995 between General Medicine and Horizon/CMS whereby General Medicine agreed to provide medical director services to skilled nursing facilities owned by Horizon/CMS for a term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three years</font><font style="font-family:inherit;font-size:10pt;">. Horizon/CMS terminated the agreement for cause six months after it was executed, and General Medicine then initiated a lawsuit against Horizon/CMS in the United States District Court for the Eastern District of Michigan in 1996 (the &#8220;Michigan Action&#8221;). General Medicine&#8217;s complaint in the Michigan Action alleged that Horizon/CMS breached the services contract by wrongfully terminating General Medicine. We acquired Horizon/CMS in 1997 and sold it to Meadowbrook Healthcare, Inc. in 2001 pursuant to a stock purchase agreement. In 2004, Meadowbrook, without the knowledge of HealthSouth, consented to the entry of a final judgment in the Michigan Action in favor of General Medicine against Horizon/CMS for the alleged wrongful termination of the contract with General Medicine in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$376 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Consent Judgment&#8221;). The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$376 million</font><font style="font-family:inherit;font-size:10pt;"> damages figure was unilaterally selected by General Medicine and was not tested or opposed by Meadowbrook. Additionally, the settlement agreement (the &#8220;Settlement&#8221;) used as the basis for the Consent Judgment provided that Meadowbrook would pay only </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$300,000</font><font style="font-family:inherit;font-size:10pt;"> to General Medicine to settle the Michigan Action and that General Medicine would seek to recover the remaining balance of the Consent Judgment solely from us. We were not a party to the Michigan Action, the Settlement negotiated by Meadowbrook, or the Consent Judgment. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The complaint filed by General Medicine against us in the Alabama Action alleges that while Horizon/CMS was our wholly owned subsidiary, General Medicine was an existing creditor of Horizon/CMS by virtue of the breach of contract claim underlying the Settlement. The complaint also alleges we caused Horizon/CMS to transfer its assets to us for less than a reasonably equivalent value or, in the alternative, with the actual intent to defraud creditors of Horizon/CMS, including General Medicine, in violation of the Alabama Uniform Fraudulent Transfer Act. General Medicine further alleges in its amended complaint that we are liable for the Consent Judgment despite not being a party to it because as Horizon/CMS&#8217;s parent we failed to observe corporate formalities in our operation and ownership of Horizon/CMS, misused our control of Horizon/CMS, stripped assets from Horizon/CMS, and engaged in other conduct which amounted to a fraud on Horizon/CMS&#8217;s creditors. General Medicine has requested relief including recovery of the unpaid amount of the Consent Judgment, the avoidance of the subject transfers of assets, attachment of the assets transferred to us, appointment of a receiver over the transferred properties, and a monetary judgment for the value of properties transferred. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have denied liability to General Medicine and asserted defenses and a counterclaim against General Medicine that the Consent Judgment is the product of collusion by General Medicine and Meadowbrook. Consequently, we assert that the Consent Judgment is not evidence of a legitimate debt owed by Horizon/CMS to General Medicine that is collectible from HealthSouth under any theory of liability.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, after we obtained discovery concerning the circumstances that led to the entry of the Consent Judgment, we filed a motion in the Michigan Action asking the court to set aside the Consent Judgment on grounds that it was the product of fraud on the court and collusion by the parties. On May 21, 2009, the court granted our motion to set aside the Consent Judgment on grounds that it was the product of fraud on the court. On March 9, 2010, General Medicine filed an appeal of the court's decision to the Sixth Circuit Court of Appeals. The parties agreed to a voluntary stay of the Alabama Action pending the outcome of General Medicine's appeal to the Sixth Circuit Court of Appeals. On April 10, 2012, the Sixth Circuit Court of Appeals reversed the lower court's ruling and reinstated the Consent Judgment. Due to the conclusion of the appeal in the Michigan Action, General Medicine requested reactivation of the Alabama Action in the Circuit Court of Jefferson County, Alabama. On January 10, 2013, we filed a motion for partial summary judgment in the Alabama Action seeking a declaration that the Consent Judgment obtained by General Medicine is not enforceable against us because, among other reasons, it was the result of collusion. On February 27, 2013, the court denied our motion. The court also indicated it concurred with the Sixth Circuit Court of Appeals that the Consent Judgment did nothing more than establish Horizon/CMS's liability to General Medicine and did not establish the amount of General Medicine&#8217;s damages claim against Horizon/CMS or the merits of General Medicine's separate fraudulent conveyance claims against HealthSouth.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 9, 2014 and on February 18, 2014, the court in the Alabama Action entered rulings based on General Medicine&#8217;s stipulation that it would not rely on the Consent Judgment to prove the amount of its damages claim against Horizon/CMS, which rulings together provided that the </font><font style="font-family:inherit;font-size:10pt;">$376 million</font><font style="font-family:inherit;font-size:10pt;"> damages figure contained in the Consent Judgment is not admissible at trial and that the issue of collusion with respect to the amount of the Consent Judgment is now moot. Instead of relying on the Consent Judgment to prove damages against Horizon/CMS, General Medicine will be required to prove the amount of any damages it has against Horizon/CMS. General Medicine did, however, indicate it would rely on the Consent Judgment to prove its status as a creditor of Horizon/CMS and that Horizon/CMS is indebted to General Medicine for breaching the 1995 services contract. On March 31, 2014, General Medicine filed a motion seeking partial summary judgment and requesting dismissal of our defenses and counterclaim which allege the Consent Judgment was the product of collusion. In opposition to the motion, we argued the Consent Judgment is collusive in its entirety, not just with respect to the </font><font style="font-family:inherit;font-size:10pt;">$376 million</font><font style="font-family:inherit;font-size:10pt;"> damages figure, and there has never been a valid adjudication that Horizon/CMS breached its 1995 services contract with General Medicine or that Horizon/CMS is indebted to General Medicine for any amount. On July&#160;15, 2014, the court issued an order denying General Medicine&#8217;s motion for partial summary judgment.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 3, 2014, the Consent Judgment expired under applicable Michigan law without renewal by General Medicine. Based on the expiration, on July 23, 2014, we filed a motion for summary judgment requesting dismissal of General Medicine&#8217;s lawsuit against us on grounds that General Medicine is no longer a &#8220;creditor&#8221; of Horizon/CMS, which is an essential element of the fraudulent transfer and alter ego claims against us, and that General Medicine&#8217;s lawsuit against us is now moot. On August&#160;13, 2014, the court denied our motion for summary judgment.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trial began on September 15, 2014. On September 16, 2014, the court issued a provisional ruling precluding us from offering any evidence at trial that the Consent Judgment was the product of collusion by General Medicine and Meadowbrook, unless General Medicine opens the door by introducing evidence of the </font><font style="font-family:inherit;font-size:10pt;">$376 million</font><font style="font-family:inherit;font-size:10pt;"> amount of the Consent Judgment. On September 18, 2014, the court granted General Medicine&#8217;s motion for a mistrial based on certain statements made during opening statements. The Alabama Action has been reset for trial beginning on March 9, 2015.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 24, 2014, we filed a petition for writ of mandamus with the Supreme Court of Alabama requesting that it review the trial court&#8217;s August 13, 2014 order denying our motion for summary judgment. A petition for writ of mandamus is a discretionary appeal, rather than an appeal as a matter of right. If the supreme court agrees to hear our petition, it will direct the parties to submit briefs on the merits and will most likely stay the March 9, 2015 trial until it renders a decision. If it does not agree to hear our petition, then the case is expected to proceed to trial on that date.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to vigorously defend ourselves against General Medicine&#8217;s claims. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Litigation&#8212;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Nichols v. HealthSouth Corp</font><font style="font-family:inherit;font-size:10pt;">. The plaintiffs allege that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiffs are seeking compensatory and punitive damages. This case was consolidated with the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> case for discovery and other pretrial purposes and was stayed in the Circuit Court on August&#160;8, 2005. The plaintiffs filed an amended complaint on November 9, 2010 to which we responded with a motion to dismiss filed on December 22, 2010. During a hearing on February&#160;24, 2012, plaintiffs&#8217; counsel indicated his intent to dismiss certain claims against us. Instead, on March 9, 2012, the plaintiffs amended their complaint to include additional securities fraud claims against HealthSouth and add several former officers to the lawsuit. On September 12, 2012, the plaintiffs further amended their complaint to request certification as a class action. One of those named officers has repeatedly attempted to remove the case to federal district court, most recently on December 11, 2012. We filed our latest motion to remand the case back to state court on January 10, 2013. On September 27, 2013, the federal court remanded the case back to state court. We intend to vigorously defend ourselves in this case. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Governmental Inquiries and Investigations&#8212;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 24, 2011, we received a document subpoena addressed to HealthSouth Hospital of Houston, a long-term acute care hospital (&#8220;LTCH&#8221;) we closed in August 2011, and issued from the Dallas, Texas office of the U.S. Department of Health and Human Services, Office of the Inspector General (the &#8220;HHS-OIG&#8221;). The subpoena stated it was in connection with an investigation of possible false or otherwise improper claims submitted to Medicare and Medicaid and requested documents and materials relating to patient admissions, length of stay, and discharge matters at this closed LTCH. We furnished the documents requested and have heard nothing from HHS-OIG since December 2012.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 4, 2013, we received document subpoenas from an office of the HHS-OIG addressed to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four</font><font style="font-family:inherit;font-size:10pt;"> of our hospitals. Those subpoenas also requested complete copies of medical records for </font><font style="font-family:inherit;font-size:10pt;">100</font><font style="font-family:inherit;font-size:10pt;"> patients treated at each of those hospitals between September 2008 and June 2012. The investigation is being conducted by the United States Department of Justice (the &#8220;DOJ&#8221;). On April 24, 2014, we received document subpoenas relating to an additional </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> of our hospitals. The new subpoenas reference substantially similar investigation subject matter as the original subpoenas and request materials from the period January 2008 through December 2013. </font><font style="font-family:inherit;font-size:10pt;">Two</font><font style="font-family:inherit;font-size:10pt;"> of the four hospitals addressed in the original set of subpoenas have received supplemental subpoenas to cover this new time period. The new subpoenas do not include requests for specific patient files, but it is expected that such requests will be made for the new group of hospitals. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the subpoenas are in connection with an investigation of alleged improper or fraudulent claims submitted to Medicare and Medicaid and request documents and materials relating to practices, procedures, protocols and policies, of certain pre- and post-admissions activities at these hospitals including, among other things, marketing functions, pre-admission screening, post-admission physician evaluations, patient assessment instruments, individualized patient plans of care, and compliance with the Medicare </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> rule. Under the Medicare rule commonly referred to as the &#8220;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> rule,&#8221; an inpatient rehabilitation hospital must treat </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> or more of its patients from at least one of a specified list of medical conditions in order to be reimbursed at the inpatient rehabilitation hospital payment rates, rather than at the lower acute care hospital payment rates. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are cooperating fully with the DOJ in connection with these subpoenas and are currently unable to predict the timing or outcome of the related investigations. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Matters&#8212;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The False Claims Act, 18 U.S.C. &#167; 287, allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings alleging violations of the False Claims Act. These </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> cases are generally sealed by the court at the time of filing. The only parties typically privy to the information contained in the complaint are the relator, the federal government, and the presiding court. It is possible that </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> lawsuits have been filed against us and that those suits remain under seal or that we are unaware of such filings or prevented by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> cases brought pursuant to the False Claims Act.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and the United States Centers for Medicare and Medicaid Services relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, HealthSouth refunding amounts to Medicare or other federal healthcare programs.</font></div></div>
us-gaap Management Fees Revenue
ManagementFeesRevenue
0 USD
us-gaap Management Fees Revenue
ManagementFeesRevenue
0 USD
CY2014Q3 us-gaap Management Fees Revenue
ManagementFeesRevenue
0 USD
CY2013Q3 us-gaap Management Fees Revenue
ManagementFeesRevenue
0 USD
CY2014Q3 us-gaap Minority Interest
MinorityInterest
143200000 USD
CY2013Q4 us-gaap Minority Interest
MinorityInterest
124100000 USD
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
33700000 USD
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
30100000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-240000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4600000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-197200000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-162300000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
374700000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
369400000 USD
us-gaap Net Income Loss
NetIncomeLoss
274700000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
58200000 USD
us-gaap Net Income Loss
NetIncomeLoss
179900000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
50100000 USD
CY2014Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
14700000 USD
CY2013Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
14100000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
44300000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
42500000 USD
us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
38400000 USD
CY2013Q3 us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
12600000 USD
CY2013Q3 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
1500000 USD
us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
5400000 USD
CY2014Q3 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
1800000 USD
us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
4100000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
257500000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
175200000 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
52500000 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
48500000 USD
hls Percentage Of Net Operating Revenues Other Income
PercentageOfNetOperatingRevenuesOtherIncome
0.016
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
500000 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
58200000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
274700000 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
52400000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
186700000 USD
us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
218800000 USD
us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
313100000 USD
CY2014Q3 us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
0 USD
us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
400000 USD
us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
21900000 USD
CY2013Q3 us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
0 USD
us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
14000000 USD
CY2014Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
688000000 USD
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
115100000 USD
CY2014Q3 us-gaap Other Assets Current
OtherAssetsCurrent
110200000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
144100000 USD
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
169500000 USD
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-1700000 USD
CY2014Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-200000 USD
CY2013Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
100000 USD
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
0 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
CY2014Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-100000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1600000 USD
CY2013Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
100000 USD
CY2014Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
0 USD
CY2013Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
-100000 USD
CY2013Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 USD
CY2014Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-100000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-800000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
500000 USD
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-200000 USD
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
CY2013Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
82200000 USD
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
241300000 USD
CY2014Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
89400000 USD
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
260200000 USD
CY2014Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
251400000 USD
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
237400000 USD
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
139700000 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
142200000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-13000000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-6000000 USD
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
600000 USD
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
200000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30100000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3200000 USD
CY2014Q3 us-gaap Other Notes Payable
OtherNotesPayable
41900000 USD
CY2013Q4 us-gaap Other Notes Payable
OtherNotesPayable
47600000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-2300000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
5500000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
43100000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
234100000 USD
us-gaap Payments For Software
PaymentsForSoftware
12600000 USD
us-gaap Payments For Software
PaymentsForSoftware
15600000 USD
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
47400000 USD
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0 USD
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
39600000 USD
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
34100000 USD
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
17200000 USD
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
4700000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
15900000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
28900000 USD
CY2014Q3 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
CY2013Q3 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
166800000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
133900000 USD
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
2500000 USD
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
8100000 USD
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
175000000 USD
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
0 USD
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
65000000 USD
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
147000000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
15200000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-4800000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
200000 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10800000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
16900000 USD
CY2014Q3 us-gaap Profit Loss
ProfitLoss
64800000 USD
us-gaap Profit Loss
ProfitLoss
317200000 USD
CY2013Q3 us-gaap Profit Loss
ProfitLoss
72300000 USD
us-gaap Profit Loss
ProfitLoss
224200000 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
994600000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
910500000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
25000000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
22400000 USD
CY2014Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
8200000 USD
CY2013Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
8000000 USD
CY2014Q3 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
12200000 USD
CY2013Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
13500000 USD
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
112000000 USD
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
110000000 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1921200000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2101100000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
19300000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
19000000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7400000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7500000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
344600000 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
449600000 USD
CY2014Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
592800000 USD
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
468700000 USD
CY2013Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
442000000 USD
CY2012Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
403500000 USD
us-gaap Stockholders Equity Other
StockholdersEquityOther
-100000 USD
us-gaap Stockholders Equity Other
StockholdersEquityOther
-2000000 USD
us-gaap Supplies Expense
SuppliesExpense
78300000 USD
CY2013Q3 us-gaap Supplies Expense
SuppliesExpense
25500000 USD
CY2014Q3 us-gaap Supplies Expense
SuppliesExpense
26600000 USD
us-gaap Supplies Expense
SuppliesExpense
82000000 USD
CY2013Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
93200000 USD
CY2014Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
93200000 USD
CY2014Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
16255544 shares
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
14654436 shares
CY2014Q3 us-gaap Treasury Stock Value
TreasuryStockValue
458100000 USD
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
404600000 USD
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-2100000 USD
CY2013Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-600000 USD
CY2014Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-500000 USD
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-4100000 USD
CY2014Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
400000 USD
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1100000 USD
us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
700000 USD
CY2014Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
100000 USD
CY2013Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
300000 USD
us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2014Q3 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0 USD
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100500000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100700000 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100400000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102400000 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86200000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88700000 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86500000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86800000 shares
hls Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value Of Equity Interest
BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValueOfEquityInterest
-14000000 USD
hls Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value Of Equity Interest
BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValueOfEquityInterest
0 USD
CY2014Q3 hls Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value Of Equity Interest
BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValueOfEquityInterest
0 USD
CY2013Q3 hls Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value Of Equity Interest
BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValueOfEquityInterest
0 USD
CY2013Q4 hls Classof Warrant Exercise Priceof Warrants
ClassofWarrantExercisePriceofWarrants
32.50
hls Percentage Of Net Operating Revenues Medicare
PercentageOfNetOperatingRevenuesMedicare
0.741
hls Premiumreceivedonbondissuance
Premiumreceivedonbondissuance
6300000 USD
hls Government Class Action And Related Settlements Gain Loss
GovernmentClassActionAndRelatedSettlementsGainLoss
-23300000 USD
CY2014Q3 hls Consolidatedcoverageratiominimum
Consolidatedcoverageratiominimum
2
CY2014Q3 hls Convertible Preferred Stock Conversion Price
ConvertiblePreferredStockConversionPrice
30.50
hls Equity In Net Income Of Consolidated Affiliates
EquityInNetIncomeOfConsolidatedAffiliates
0 USD
hls Equity In Net Income Of Consolidated Affiliates
EquityInNetIncomeOfConsolidatedAffiliates
0 USD
CY2014Q3 hls Equity In Net Income Of Consolidated Affiliates
EquityInNetIncomeOfConsolidatedAffiliates
0 USD
CY2013Q3 hls Equity In Net Income Of Consolidated Affiliates
EquityInNetIncomeOfConsolidatedAffiliates
0 USD
hls Equity Method Investment Summarized Financial Information Operating Expenses
EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
-22700000 USD
hls Equity Method Investment Summarized Financial Information Operating Expenses
EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
-32500000 USD
CY2013Q3 hls Equity Method Investment Summarized Financial Information Operating Expenses
EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
-10300000 USD
CY2014Q3 hls Equity Method Investment Summarized Financial Information Operating Expenses
EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
-3300000 USD
CY2014Q1 hls Expirationof Warrants
ExpirationofWarrants
100000 shares
CY2013Q3 hls Government Class Action And Related Settlements Gain Loss
GovernmentClassActionAndRelatedSettlementsGainLoss
-21300000 USD
hls Government Class Action And Related Settlements Gain Loss
GovernmentClassActionAndRelatedSettlementsGainLoss
-800000 USD
CY2014Q3 hls Government Class Action And Related Settlements Gain Loss
GovernmentClassActionAndRelatedSettlementsGainLoss
0 USD
hls Income Loss From Continuing Operations Attributable To Common Shareholders Basic
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
170300000 USD
CY2013Q3 hls Income Loss From Continuing Operations Attributable To Common Shareholders Basic
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
52800000 USD
CY2014Q3 hls Income Loss From Continuing Operations Attributable To Common Shareholders Basic
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
48900000 USD
hls Income Loss From Continuing Operations Attributable To Common Shareholders Basic
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
254600000 USD
CY2014Q3 hls Income Loss From Continuing Operations Attributable To Common Shareholders Diluted
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
53300000 USD
hls Income Loss From Continuing Operations Attributable To Common Shareholders Diluted
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
183900000 USD
hls Income Loss From Continuing Operations Attributable To Common Shareholders Diluted
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
275900000 USD
CY2013Q3 hls Income Loss From Continuing Operations Attributable To Common Shareholders Diluted
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
59100000 USD
hls Net Income Loss Availableto Common Stockholders
NetIncomeLossAvailabletoCommonStockholders
253400000 USD
CY2014Q3 hls Net Income Loss Availableto Common Stockholders
NetIncomeLossAvailabletoCommonStockholders
48000000 USD
CY2013Q3 hls Net Income Loss Availableto Common Stockholders
NetIncomeLossAvailabletoCommonStockholders
51900000 USD
hls Net Income Loss Availableto Common Stockholders
NetIncomeLossAvailabletoCommonStockholders
173100000 USD
CY2014Q3 hls Net Operating Revenues Less Provision For Doubtful Accounts
NetOperatingRevenuesLessProvisionForDoubtfulAccounts
588700000 USD
hls Net Operating Revenues Less Provision For Doubtful Accounts
NetOperatingRevenuesLessProvisionForDoubtfulAccounts
1767500000 USD
CY2013Q3 hls Net Operating Revenues Less Provision For Doubtful Accounts
NetOperatingRevenuesLessProvisionForDoubtfulAccounts
556000000 USD
hls Premiumreceivedonbondissuance
Premiumreceivedonbondissuance
0 USD
hls Net Operating Revenues Less Provision For Doubtful Accounts
NetOperatingRevenuesLessProvisionForDoubtfulAccounts
1678700000 USD
CY2014Q3 hls Number Of General Or Limited Partnerships Limited Liability Companies Or Joint Ventures
NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures
8 facilities
CY2014Q3 hls Number Of Partially Owned Subsidiaries Nonconsolidated
NumberOfPartiallyOwnedSubsidiariesNonconsolidated
9 facilities
CY2014Q3 hls Occupancy Cost
OccupancyCost
10300000 USD
hls Occupancy Cost
OccupancyCost
31100000 USD
hls Occupancy Cost
OccupancyCost
35800000 USD
CY2013Q3 hls Occupancy Cost
OccupancyCost
11700000 USD
CY2007Q4 hls Option Contract Annual Premium
OptionContractAnnualPremium
0.15
CY2007Q4 hls Option Contract Exercisable
OptionContractExercisable
0.30
hls Ownership Percentage Of Subsidiary Guarantors
OwnershipPercentageOfSubsidiaryGuarantors
1.00
CY2013Q3 hls Percentage Of Net Operating Revenues Managed Care
PercentageOfNetOperatingRevenuesManagedCare
0.187
hls Percentage Of Net Operating Revenues Managed Care
PercentageOfNetOperatingRevenuesManagedCare
0.185
hls Percentage Of Net Operating Revenues Managed Care
PercentageOfNetOperatingRevenuesManagedCare
0.186
CY2014Q3 hls Percentage Of Net Operating Revenues Managed Care
PercentageOfNetOperatingRevenuesManagedCare
0.188
hls Percentage Of Net Operating Revenues Medicaid
PercentageOfNetOperatingRevenuesMedicaid
0.012
hls Percentage Of Net Operating Revenues Medicaid
PercentageOfNetOperatingRevenuesMedicaid
0.018
CY2013Q3 hls Percentage Of Net Operating Revenues Medicaid
PercentageOfNetOperatingRevenuesMedicaid
0.015
CY2014Q3 hls Percentage Of Net Operating Revenues Medicaid
PercentageOfNetOperatingRevenuesMedicaid
0.022
CY2014Q3 hls Percentage Of Net Operating Revenues Medicare
PercentageOfNetOperatingRevenuesMedicare
0.735
CY2013Q3 hls Percentage Of Net Operating Revenues Medicare
PercentageOfNetOperatingRevenuesMedicare
0.741
hls Percentage Of Net Operating Revenues Medicare
PercentageOfNetOperatingRevenuesMedicare
0.745
CY2013Q3 hls Percentage Of Net Operating Revenues Other Income
PercentageOfNetOperatingRevenuesOtherIncome
0.016
CY2014Q3 hls Percentage Of Net Operating Revenues Other Income
PercentageOfNetOperatingRevenuesOtherIncome
0.015
hls Percentage Of Net Operating Revenues Other Income
PercentageOfNetOperatingRevenuesOtherIncome
0.017
hls Percentage Of Net Operating Revenues Other Third Party Payors
PercentageOfNetOperatingRevenuesOtherThirdPartyPayors
0.017
hls Percentage Of Net Operating Revenues Other Third Party Payors
PercentageOfNetOperatingRevenuesOtherThirdPartyPayors
0.017
CY2014Q3 hls Percentage Of Net Operating Revenues Other Third Party Payors
PercentageOfNetOperatingRevenuesOtherThirdPartyPayors
0.018
CY2013Q3 hls Percentage Of Net Operating Revenues Other Third Party Payors
PercentageOfNetOperatingRevenuesOtherThirdPartyPayors
0.017
CY2014Q3 hls Percentage Of Net Operating Revenues Patients
PercentageOfNetOperatingRevenuesPatients
0.011
hls Percentage Of Net Operating Revenues Patients
PercentageOfNetOperatingRevenuesPatients
0.011
CY2013Q3 hls Percentage Of Net Operating Revenues Patients
PercentageOfNetOperatingRevenuesPatients
0.011
hls Percentage Of Net Operating Revenues Patients
PercentageOfNetOperatingRevenuesPatients
0.010
CY2014Q3 hls Percentage Of Net Operating Revenues Total
PercentageOfNetOperatingRevenuesTotal
1.000
hls Percentage Of Net Operating Revenues Total
PercentageOfNetOperatingRevenuesTotal
1.000
CY2013Q3 hls Percentage Of Net Operating Revenues Total
PercentageOfNetOperatingRevenuesTotal
1.000
hls Percentage Of Net Operating Revenues Total
PercentageOfNetOperatingRevenuesTotal
1.000
hls Percentage Of Net Operating Revenues Workers Compensation
PercentageOfNetOperatingRevenuesWorkersCompensation
0.013
CY2013Q3 hls Percentage Of Net Operating Revenues Workers Compensation
PercentageOfNetOperatingRevenuesWorkersCompensation
0.013
CY2014Q3 hls Percentage Of Net Operating Revenues Workers Compensation
PercentageOfNetOperatingRevenuesWorkersCompensation
0.011
hls Percentage Of Net Operating Revenues Workers Compensation
PercentageOfNetOperatingRevenuesWorkersCompensation
0.012
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000785161
CY2013Q3 hls Professional Fees Accounting Tax And Legal
ProfessionalFeesAccountingTaxAndLegal
4200000 USD
CY2014Q3 hls Professional Fees Accounting Tax And Legal
ProfessionalFeesAccountingTaxAndLegal
4000000 USD
hls Professional Fees Accounting Tax And Legal
ProfessionalFeesAccountingTaxAndLegal
7800000 USD
hls Professional Fees Accounting Tax And Legal
ProfessionalFeesAccountingTaxAndLegal
7600000 USD
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014Q3 hls Seniorsecuredleverageratiomaximum
Seniorsecuredleverageratiomaximum
1.75
hls Treasury Stock Reacquired
TreasuryStockReacquired
9700000 USD
hls Treasury Stock Reacquired
TreasuryStockReacquired
5800000 USD
hls Treasury Stock Value Acquired Cost Method Common Stock
TreasuryStockValueAcquiredCostMethodCommonStock
43100000 USD
hls Treasury Stock Value Acquired Cost Method Common Stock
TreasuryStockValueAcquiredCostMethodCommonStock
234100000 USD
hls Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromPriorPeriodTaxPositions
300000 USD
hls Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedIncreasesResultingFromPriorPeriodTaxPositions
100000 USD
hls Warrants Exercised Value
WarrantsExercisedValue
6300000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
87752931 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2013Q2 dei Entity Public Float
EntityPublicFloat
2500000000 USD
dei Entity Registrant Name
EntityRegistrantName
HEALTHSOUTH CORP
dei Entity Voluntary Filers
EntityVoluntaryFilers
No
dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes

Files In Submission

Name View Source Status
0000785161-14-000067-index-headers.html Edgar Link pending
0000785161-14-000067-index.html Edgar Link pending
0000785161-14-000067.txt Edgar Link pending
0000785161-14-000067-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hls-20140930.xml Edgar Link completed
hls-20140930.xsd Edgar Link pending
hls-20140930_cal.xml Edgar Link unprocessable
hls-20140930_def.xml Edgar Link unprocessable
hls-20140930_lab.xml Edgar Link unprocessable
hls-20140930_pre.xml Edgar Link unprocessable
hls10q93014.htm Edgar Link pending
hls10q93014ex251.htm Edgar Link pending
hls10q93014ex311.htm Edgar Link pending
hls10q93014ex312.htm Edgar Link pending
hls10q93014ex321.htm Edgar Link pending
hls10q93014ex322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending